Dihydromyricetin increases endothelial nitric oxide production and inhibits atherosclerosis through microRNA-21 in apolipoprotein E-deficient mice.

ABSTRACT: Natural products were extracted from traditional Chinese herbal emerging as potential therapeutic drugs for treating cardiovascular diseases. This study examines the role and underlying mechanism of dihydromyricetin (DMY), a natural compound extracted from Ampelopsis grossedentata, in atherosclerosis. DMY treatment significantly inhibits atherosclerotic lesion formation, proinflammatory gene expression and the influx of lesional macrophages and CD4-positive T cells in the vessel wall and hepatic inflammation, whereas increases nitric oxide (NO) production and improves lipid metabolism in apolipoprotein E-deficient (Apoe^{- / -} ) mice. Yet, those protective effects are abrogated by using NOS inhibitor L-NAME in Apoe^{- / -} mice r

SUBMITTER: Yang D 

PROVIDER: S-EPMC7214150 | biostudies-literature | 2020 May

REPOSITORIES: biostudies-literature